Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Richard A. Furie, MD

Chief of the Division of Rheumatology
Northwell
Manhasset, NY, United States

Professional Title:
Chief, Division of Rheumatology, Northwell Health
Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell

Bio:
Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital’s SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For twenty years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with his colleagues and trainees.

Presentation(s):

  • 0665: Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb Company: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Advisor or Review Panel Member (Ongoing); Genentech: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kezar: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • 0664: Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb Company: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Advisor or Review Panel Member (Ongoing); Genentech: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kezar: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • ITS6: Advances in SLE Management: Expert Perspectives on Targeting DORIS Remission and Emerging Clinical Data for a Novel Treatment

    Sunday, October 26, 2025
    5:30 PM - 7:30 PM Central Time

    Disclosure information not submitted.

  • 1542: Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-week Phase 3 Trial

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb Company: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Advisor or Review Panel Member (Ongoing); Genentech: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kezar: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • ITS13: Incorporating New Data Into Patient Care for Lupus Nephritis

    Monday, October 27, 2025
    5:30 PM - 7:30 PM Central Time

    Disclosure information not submitted.

  • ITS14: Incorporating New Data Into Patient Care for Lupus Nephritis

    Monday, October 27, 2025
    5:30 PM - 7:30 PM Central Time

    Disclosure information not submitted.

  • 2467: Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb Company: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Advisor or Review Panel Member (Ongoing); Genentech: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kezar: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • 2466: Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb Company: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Advisor or Review Panel Member (Ongoing); Genentech: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kezar: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)